Rachel E. Sanborn

All papers authored by Rachel E. Sanborn

This paper was not found in any repository, but could be made available legally by the author.

2023 Byoung Chul Cho

, Dong-Wan Kim

, Alexander I. Spira, Jorge E. Gomez

, Eric B. Haura, Sang-We Kim, Rachel E. Sanborn

, Eun Kyung Cho, Ki Hyeong Lee, Anna Minchom

, Jong-Seok Lee, Ji-Youn Han, Misako Nagasaka, Joshua K. Sabari, Sai-Hong Ignatius Ou

and 9 other authors

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

Upload

This paper is made freely available by the publisher.

Paolo Antonio Ascierto

, Evan J. Lipson

, Reinhard Dummer

, James Larkin

, Georgina V. Long

, Rachel E. Sanborn

, Vanna Chiarion-Sileni

, Brigitte Dréno

, Stéphane Dalle, Dirk Schadendorf

, Margaret K. Callahan, Marta Nyakas

, Victoria Atkinson, Carlos Alberto Gomez-Roca

, Naoya Yamazaki

and 7 other authors

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

Download from doi.org

2021 Keunchil Park

, Eric B. Haura, Natasha B. Leighl

, Paul Mitchell, Catherine A. Shu

, Nicolas Girard, Santiago Viteri, Ji-Youn Han

, Sang-We Kim, Chee Khoon Lee

, Joshua K. Sabari

, Alexander I. Spira

, Tsung-Ying Yang, Dong-Wan Kim

, Ki Hyeong Lee

and 19 other authors

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Download from doi.org

Rachel E. Sanborn

, Omid Hamid, Elisabeth Ge de Vries, Patrick A. Ott, Javier Garcia-Corbacho, Valentina Boni, Johanna Bendell, Karen A. Autio, Daniel C. Cho, Ruth Plummer, Mark Stroh, Lawrence Lu, Fiona Thistlethwaite

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

Download from doi.org

Melissa Johnson, Anthony El-Khoueiry, Navid Hafez, Nehal Lakhani, Hirva Mamdani

, Jordi Rodon

, Rachel E. Sanborn

, Javier Garcia-Corbacho

, Valentina Boni

, Mark Stroh, Alison L. Hannah, Song Wang, Henry Castro, Alexander Spira

Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies

Download from aacrjournals.org

2020 Alexey Berezhnoy

, Bradley J. Sumrow, Kurt Stahl, Kalpana Shah, Daorong Liu, Jonathan Li, Su-Shin Hao, Anushka De Costa, Sanjeev Kaul, Johanna Bendell, Gregory M. Cote, Jason J. Luke, Rachel E. Sanborn

, Manish R. Sharma, Francine Chen and 4 other authors

Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule

Upload

2018 Leora Horn, Jeffrey R. Infante, Karen L. Reckamp

, George R. Blumenschein, Ticiana A. Leal, Saiama N. Waqar, Barbara J. Gitlitz, Rachel E. Sanborn

, Jennifer G. Whisenant, Liping Du, Joel W. Neal, Jon P. Gockerman, Gary Dukart, Kimberly Harrow, Chris Liang and 4 other authors

Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Download from aacrjournals.org

2016 Rachel E. Sanborn

, Jyoti D. Patel, Gregory A. Masters, Nagesh Jayaram, Anthony Stephens, Michael Guarino, Jamal Misleh, Jingwei Wu, Nasser Hanna

A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113

Upload

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

All papers authored by Rachel E. Sanborn